NYSE:EVH - Evolent Health Stock Price, Forecast & News

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health Inc (NYSE:EVH) posted its quarterly earnings results on Tuesday, November, 5th. The technology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. The technology company had revenue of $220.14 million for the quarter, compared to analyst estimates of $217.90 million. Evolent Health had a negative net margin of 15.02% and a negative return on equity of 6.93%. The company's quarterly revenue was up 46.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. View Evolent Health's Earnings History.

Evolent Health is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Evolent Health.

Evolent Health will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 Wall Street analysts have issued 1-year target prices for Evolent Health's stock. Their forecasts range from $10.00 to $19.00. On average, they anticipate Evolent Health's share price to reach $14.89 in the next year. This suggests a possible upside of 28.8% from the stock's current price. View Analyst Price Targets for Evolent Health.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evolent Health.

Press coverage about EVH stock has trended somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evolent Health earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave media coverage about the technology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Evolent Health.

Some companies that are related to Evolent Health include Mantech International (MANT), R1 RCM (RCM), Franklin Covey (FC), Jupai (JP), PHI Group (PHIL) and Rainmaker Systems (VCTL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Energy Transfer LP Unit (ET), Advanced Micro Devices (AMD), Transocean (RIG) and NVIDIA (NVDA).

(EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Credit Suisse AG (4.43%), Eagle Asset Management Inc. (4.03%), Riverbridge Partners LLC (3.42%), Sectoral Asset Management Inc (2.36%), Formula Growth Ltd. (2.26%) and Bank of New York Mellon Corp (1.90%). Company insiders that own Evolent Health stock include Cheryl Scott, Doug S Aron, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Lydia Stone, Michael D'amato, Seth Blackley, Thomas Peterson III and Unitedhealth Group Inc. View Institutional Ownership Trends for Evolent Health.

EVH stock was sold by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Bank of America Corp DE, Riverbridge Partners LLC, Royce & Associates LP, Peregrine Capital Management LLC, Rock Point Advisors LLC, Oppenheimer & Co. Inc. and White Pine Investment CO. View Insider Buying and Selling for Evolent Health.

EVH stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Point72 Asset Management L.P., California Public Employees Retirement System, Sectoral Asset Management Inc, Eagle Asset Management Inc., Formula Growth Ltd., Dean Capital Investments Management LLC and Credit Suisse AG. Company insiders that have bought Evolent Health stock in the last two years include Doug S Aron, Kenneth A Samet, Michael D'amato and Seth Blackley. View Insider Buying and Selling for Evolent Health.

Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EVH stock can currently be purchased for approximately $11.56.

Evolent Health has a market capitalization of $978.08 million and generates $627.06 million in revenue each year. The technology company earns $-52,660,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Evolent Health employs 3,800 workers across the globe.View Additional Information About Evolent Health.

The official website for Evolent Health is http://www.evolenthealth.com/.

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000.